| Market Cap | 2.97B | P/E | 206.67 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -55.36M | Forward P/E | 30.00 | EPS next Y | 20.90% | 50D Avg Chg | -2.00% |
| Sales | 354.34M | PEG | 1.12 | EPS past 5Y | 41.03% | 200D Avg Chg | -1.00% |
| Dividend | N/A | Price/Book | 2.74 | EPS next 5Y | 33.70% | 52W High Chg | -25.00% |
| Recommedations | 2.50 | Quick Ratio | 2.56 | Shares Outstanding | 160.19M | 52W Low Chg | 75.00% |
| Insider Own | 2.99% | ROA | 0.56% | Shares Float | 109.07M | Beta | 1.63 |
| Inst Own | 98.39% | ROE | -5.21% | Shares Shorted/Prior | 5.67M/4.69M | Price | 18.60 |
| Gross Margin | 60.20% | Profit Margin | -15.62% | Avg. Volume | 1,150,941 | Target Price | 19.72 |
| Oper. Margin | -13.56% | Earnings Date | May 7 | Volume | 482,028 | Change | -2.62% |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
| Keybanc | Overweight | Apr 10, 24 |
| JMP Securities | Market Perform | Apr 4, 24 |
| UBS | Neutral | Mar 1, 24 |
| Jefferies | Hold | Mar 1, 24 |
| Leerink Partners | Market Perform | Feb 26, 24 |
| Barclays | Equal-Weight | Jan 25, 24 |
| UBS | Neutral | Dec 7, 23 |
| Keybanc | Sector Weight | Dec 5, 23 |
| Stephens & Co. | Overweight | Oct 11, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Traynor Richard M. | SVP AND GENERAL COUN.. SVP AND GENERAL COUNSEL | Dec 26 | Sell | 18 | 6,000 | 108,000 | 171,368 | 12/27/23 |
| SMITH PATRICK F | PRESIDENT, INTEGRATE.. PRESIDENT, INTEGRATED DRUG DEV | Jun 05 | Sell | 21.55 | 19,104 | 411,691 | 59,975 | 06/06/23 |
| Traynor Richard M. | SVP AND GENERAL COUN.. SVP AND GENERAL COUNSEL | Apr 14 | Sell | 23.66 | 5,000 | 118,300 | 182,368 | 04/17/23 |
| McLean Stephen M. | Director Director | Aug 19 | Buy | 16.32 | 20,000 | 326,400 | 42,000 | 08/23/22 |
| Schemick Michael Andrew | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Aug 17 | Buy | 16.64 | 25,000 | 416,000 | 517,870 | 08/18/22 |
| SMITH PATRICK F | PRESIDENT, INTEGRATE.. PRESIDENT, INTEGRATED DRUG DEV | Aug 16 | Sell | 17.71 | 10,000 | 177,100 | 78,490 | 08/18/22 |
| EQT Avatar Parent L.P. | 10% Owner 10% Owner | Aug 16 | Sell | 17.38 | 6,004,418 | 104,356,785 | 29,954,521 | 08/17/22 |
| EQT Avatar Parent L.P. | 10% Owner 10% Owner | May 31 | Sell | 19.00 | 1,500,000 | 28,500,000 | 35,958,939 | 06/01/22 |
| Traynor Richard M. | SVP AND GENERAL COUN.. SVP AND GENERAL COUNSEL | Mar 16 | Sell | 20 | 3,000 | 60,000 | 211,287 | 03/18/22 |
| Feehery William F | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Mar 11 | Sell | 20.29 | 27,515 | 558,279 | 2,240,536 | 03/14/22 |
| Feehery William F | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 18 | Sell | 23.62 | 75,000 | 1,771,500 | 2,268,051 | 02/22/22 |
| Feehery William F | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 17 | Sell | 24.75 | 90,000 | 2,227,500 | 2,343,051 | 02/22/22 |
| SLAINE MASON P | Director Director | Feb 01 | Sell | 26.67 | 50,000 | 1,333,500 | 1,592,797 | 02/02/22 |
| Edge Justin | PRES., REGULATORY &.. PRES., REGULATORY & ACCESS | Jan 20 | Sell | 27.50 | 5,000 | 137,500 | 397,090 | 01/21/22 |
| Traynor Richard M. | SVP AND GENERAL COUN.. SVP AND GENERAL COUNSEL | Jan 18 | Sell | 27.44 | 5,000 | 137,200 | 217,287 | 01/20/22 |
| Schemick Michael Andrew | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 15 | Sell | 38.2 | 66,666 | 2,546,641 | 496,843 | 11/16/21 |